Announced Mon, 27 Jul · 14:14 IST
Epigral Q1FY27: Revenue up 15%, PAT up 25%, new capex approved
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
—1-day move
₹1163.00
prior close
₹1179.50
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.7-0.0-0.4-0.8——————————
Up moveDown movePending
AI summary
Epigral posted Q1FY27 revenue of Rs 709 Cr (+15% YoY) with EBITDA at Rs 179 Cr (+10%) and PAT at Rs 99 Cr (+25%). EBITDA margin held at 25%, plant utilization above 80%. Net debt to EBITDA improved to 0.8x. Board approved new capex for Epoxy Resin (1,25,000 TPA) and Multi-Purpose Plant, both expected by H2FY28. CPVC and ECH expansions on track for Q2FY27. Target: 70% revenue from derivatives and specialty chemicals by FY28E, up from 48% in FY26.
Likely market impact
Strong quarterly results with multi-year growth visibility from capacity expansions and shift to specialty chemicals. Positive for shareholders.